Pulmonary Hypertension

129

Pipeline Programs↗

35

Active Trials↗

45

Companies Involved↗

Pulmonary Hypertension is a highly competitive landscape with 129 programs across 45 companies. The most active players are Hope Pharmaceuticals, WestVac Biopharma Co., Ltd., Vitarine. 33 therapies are approved with 23 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

48/100

Mech. Concentration

9/100

Completion Rate

66/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Hope Pharmaceuticals

1 program

WestVac Biopharma Co., Ltd.

1 program

Vitarine

1 program

Merck & Co.

2 programs

Salubris Biotherapeutics Inc

1 program

Apollo Therapeutics Ltd

1 program

Analysis

Modality Breakdown

96%

Small molecule

138 of 144 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 144 classified programs, each share of the total. Modality classified for 98% of 155 pipeline programs.

Analysis

Trial Status

213

clinical trials

Completed99 · 46%

Terminated36 · 17%

Unknown status28 · 13%

Recruiting22 · 10%

Withdrawn14 · 7%

Not yet recruiting10 · 5%

Other4 · 2%

Clinical Trials

Trial Activity

213 trials

The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

Recruiting·—·Phase 4·NCT07359599·306 enrolled

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

Recruiting·SSalubris Biotherapeutics Inc·Phase 2·NCT07221513·30 enrolled

Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension

Recruiting·LLee's Pharmaceutical Limited·N/A·NCT07099144·120 enrolled

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Recruiting·—·Phase 2/3·NCT07462260·100 enrolled

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Recruiting·PPulnovo Medical (Wuxi) Co., Ltd.·Phase 3·NCT05824923·264 enrolled

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06814145·130 enrolled

Pulmonary Hypertension SOLAR

Recruiting·—·Phase 2·NCT04778046·30 enrolled

Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension

Recruiting·CChina National Center for Cardiovascular Diseases·N/A·NCT06429579·120 enrolled

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

Recruiting·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT05825417·40 enrolled

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Recruiting·AApollo Therapeutics Ltd·Phase 2·NCT06846554·48 enrolled

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Recruiting·UUniversity of Washington·Phase 2·NCT06053580·60 enrolled

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

Recruiting·UUniversity of California, Davis·Phase 4·NCT07322133·30 enrolled

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

Recruiting·ZZagazig University·Phase 4·NCT04484675·38 enrolled

Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn

Recruiting·SSohag University·Phase 1/2·NCT04898114·40 enrolled

A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Recruiting·PPulnovo Medical, Inc.·Preclinical·NCT07214376·750 enrolled

Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)